|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001675,
umls-concept:C0001792,
umls-concept:C0004096,
umls-concept:C0013072,
umls-concept:C0034656,
umls-concept:C0073992,
umls-concept:C0087111,
umls-concept:C0117996,
umls-concept:C0439234,
umls-concept:C0687676,
umls-concept:C0936012,
umls-concept:C1276807,
umls-concept:C1707455
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2010-7-14
|
|
pubmed:abstractText |
Three fixed maintenance-dose inhaled corticosteroid/long-acting beta(2)-agonist (ICS/LABA) combinations for the treatment of asthma are currently available: salmeterol/fluticasone propionate (Seretide/Advair/Adoair) budesonide/formoterol (Symbicort) and beclometasone/formoterol (Foster). All of these combinations have proven efficacy in terms of controlling symptoms, improving lung function and reducing the rate of exacerbations compared with ICSs and LABAs administered separately. Budesonide/formoterol is also approved for use as maintenance and reliever therapy in a number of countries (Symbicort SMART). Many of the studies supporting the use of budesonide/formoterol combination therapies have included populations of adolescents and adults aged >11 years.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic beta-Agonists,
http://linkedlifedata.com/resource/pubmed/chemical/Albuterol,
http://linkedlifedata.com/resource/pubmed/chemical/Androstadienes,
http://linkedlifedata.com/resource/pubmed/chemical/Bronchodilator Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Budesonide,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/Ethanolamines,
http://linkedlifedata.com/resource/pubmed/chemical/Glucocorticoids,
http://linkedlifedata.com/resource/pubmed/chemical/fluticasone, salmeterol drug...,
http://linkedlifedata.com/resource/pubmed/chemical/formoterol
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1173-2563
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
30
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
565-79
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:20593912-Administration, Inhalation,
pubmed-meshheading:20593912-Adolescent,
pubmed-meshheading:20593912-Adrenergic beta-Agonists,
pubmed-meshheading:20593912-Adult,
pubmed-meshheading:20593912-Aged,
pubmed-meshheading:20593912-Aged, 80 and over,
pubmed-meshheading:20593912-Albuterol,
pubmed-meshheading:20593912-Androstadienes,
pubmed-meshheading:20593912-Asthma,
pubmed-meshheading:20593912-Bronchodilator Agents,
pubmed-meshheading:20593912-Budesonide,
pubmed-meshheading:20593912-Double-Blind Method,
pubmed-meshheading:20593912-Drug Combinations,
pubmed-meshheading:20593912-Emergency Service, Hospital,
pubmed-meshheading:20593912-Ethanolamines,
pubmed-meshheading:20593912-Female,
pubmed-meshheading:20593912-Glucocorticoids,
pubmed-meshheading:20593912-Hospitalization,
pubmed-meshheading:20593912-Humans,
pubmed-meshheading:20593912-Kaplan-Meier Estimate,
pubmed-meshheading:20593912-Lung,
pubmed-meshheading:20593912-Male,
pubmed-meshheading:20593912-Middle Aged,
pubmed-meshheading:20593912-Proportional Hazards Models,
pubmed-meshheading:20593912-Quality of Life,
pubmed-meshheading:20593912-Time Factors,
pubmed-meshheading:20593912-Treatment Outcome,
pubmed-meshheading:20593912-Young Adult
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged > or =16 years with asthma: post hoc analysis of a randomized, double-blind study.
|
|
pubmed:affiliation |
Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland. piotr.kuna@umed.lodz.pl
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
